Synthetic RNA vaccine technology has the potential to substantially shorten the time frame between pathogen sequence acquisition in the field to vaccine manufacturing.
Synthetic RNA vaccine technology has the potential to substantially shorten the time frame between pathogen sequence acquisition in the field to vaccine manufacturing.
Global Shield is a 501(c)(3) nonprofit, fiscally sponsored by Social and Environmental Entrepreneurs (SEE). Our organization’s growth and international outreach will depend on continued support from donors, and we appreciate any support you can provide.
Privacy Policy | Branding & Website by Yes Creative | © Global Shield 2024